MiR-484 (36), miR-145 (37) and miR-211 (38) have recently been reported to inhibit EMT and invasion of cervical cancer cells via targeting ZEB1/SMAD2, SMAD-interacting protein 1 (SIP1) and mucin 4 (MUC4), respectively. Here, ZEB2 is linked to cervical cancer.